Araim Pharmaceuticals’ Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis

Vault BioventuresClinical Development, Industry NewsLeave a Comment

Araim Pharmaceuticals cibinetide (ara 290)
Share This:

The double blind, randomized, placebo-controlled, two-center study published in Investigative Ophthalmology & Visual Science assessed the safety and efficacy of daily subcutaneous 1, 4, 8 mg cibinetide or placebo for 28 days in 64 patients … Read More